PT1176971E - Utilizacao de phyllanthus para o tratamento de processos inflamatorios e fibroticos cronicos - Google Patents

Utilizacao de phyllanthus para o tratamento de processos inflamatorios e fibroticos cronicos

Info

Publication number
PT1176971E
PT1176971E PT00927102T PT00927102T PT1176971E PT 1176971 E PT1176971 E PT 1176971E PT 00927102 T PT00927102 T PT 00927102T PT 00927102 T PT00927102 T PT 00927102T PT 1176971 E PT1176971 E PT 1176971E
Authority
PT
Portugal
Prior art keywords
phyllanthus
inflammatory
treatment
chronic processes
fibrotic chronic
Prior art date
Application number
PT00927102T
Other languages
English (en)
Inventor
Wagner Hildebert
Vollmar Angelika
Manns Michael
Gebhardt Rolf
Bahr Matthias
Buniatian Gayane Hrachia
Original Assignee
Phytrix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytrix Ag filed Critical Phytrix Ag
Publication of PT1176971E publication Critical patent/PT1176971E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT00927102T 1999-04-29 2000-04-28 Utilizacao de phyllanthus para o tratamento de processos inflamatorios e fibroticos cronicos PT1176971E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19919585A DE19919585A1 (de) 1999-04-29 1999-04-29 Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen

Publications (1)

Publication Number Publication Date
PT1176971E true PT1176971E (pt) 2005-01-31

Family

ID=7906333

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00927102T PT1176971E (pt) 1999-04-29 2000-04-28 Utilizacao de phyllanthus para o tratamento de processos inflamatorios e fibroticos cronicos

Country Status (13)

Country Link
US (1) US6586015B1 (pt)
EP (2) EP1176971B1 (pt)
JP (2) JP2002543139A (pt)
CN (2) CN1364085A (pt)
AT (1) ATE275411T1 (pt)
AU (2) AU4559300A (pt)
BR (2) BR0010604A (pt)
CA (2) CA2372223A1 (pt)
DE (2) DE19919585A1 (pt)
ES (1) ES2226831T3 (pt)
MX (2) MXPA01010982A (pt)
PT (1) PT1176971E (pt)
WO (2) WO2000066135A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030139A1 (de) * 2000-06-20 2002-01-10 Cmi Ag Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae
CA2424930A1 (en) * 2000-10-06 2003-04-04 Cmi-Centers For Medical Innovation Ag Method for producing phyllanthus extracts
ES2261507T3 (es) * 2000-10-06 2006-11-16 Phytrix Inc. Compuestos derivados de phyllanthus para la prevencion y/o el tratamiento de enfermedades asociadas con un retrovirus.
DE10120627A1 (de) * 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
US20050064053A1 (en) * 2002-11-08 2005-03-24 Em Industries Enriched aqueous components of emblica officinalis
JP2006514670A (ja) 2003-03-03 2006-05-11 稲畑香料株式会社 血清高比重リボタンパク質を増加させるための方法及び技術
JP5508656B2 (ja) * 2004-07-16 2014-06-04 太陽化学株式会社 最終糖化産物生成阻害組成物
TW200607517A (en) * 2004-08-17 2006-03-01 Hepaguard Biotechnology Int L Co Ltd Medicinal composition capable of suppressing proliferation or metastasis of tumor cells
WO2006131932A1 (en) * 2005-06-09 2006-12-14 Mmi Corporation Herbal formulation capable of preventing alcohol-induced hangover, methods of preparing the same and use thereof
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
EP2175871B1 (en) * 2007-07-18 2016-08-31 Council of Scientific & Industrial Research A synergistic herbal composition for treatment of rheumatic and musculo-skeletal disorders (rmsds)
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
WO2009081411A2 (en) * 2007-12-26 2009-07-02 Rainbow Medical Nitric oxide generation to treat female sexual dysfunction
US20090198271A1 (en) * 2008-01-31 2009-08-06 Rainbow Medical Ltd. Electrode based filter
US7749284B2 (en) * 2008-04-28 2010-07-06 Aveda Corporation Oxidative hair dye compositions, methods and products
EP2116253A1 (en) * 2008-05-07 2009-11-11 Phytrix JV, LLC Novel phyllanthus extract
US8916209B2 (en) * 2009-10-02 2014-12-23 Johnson & Johnson Consumer Companies, Inc. Extracts of Phyllanthus niruri
US20110202108A1 (en) * 2010-02-18 2011-08-18 Rainbow Medical Ltd. Electrical menorrhagia treatment
US20130064912A1 (en) * 2011-09-09 2013-03-14 Jon Barron Formulation for alleviation of kidney stone and gallstone symptoms
US10286022B2 (en) 2013-10-08 2019-05-14 Benny Antony Medicinal composition of extract of seed of emblica officinalis and method of preparing the same
US8980340B1 (en) 2013-10-08 2015-03-17 Benny Antony Medicinal composition of extract of seed of emblica officinalis and method of preparing the same
IN2013CH04565A (pt) 2013-10-08 2015-09-25 Benny Antony
CN105168314A (zh) * 2015-09-10 2015-12-23 福建农林大学 一种复方叶下珠制剂及其在犬日粮上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388457A (en) 1982-02-11 1983-06-14 University Patents, Inc. Phyllanthostatin compounds
US4673575A (en) 1985-04-26 1987-06-16 Fox Chase Cancer Center Composition, pharmaceutical preparation and method for treating viral hepatitus
US4937074A (en) 1988-03-29 1990-06-26 Fox Chase Cancer Center Method of treating retrovirus infection
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US5571441A (en) 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
US6136316A (en) 1996-04-17 2000-10-24 Dabur Research Foundation Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
PT903148E (pt) 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
GB2355932B (en) 1999-04-12 2004-01-07 Univ Madras A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation

Also Published As

Publication number Publication date
WO2000066134A1 (de) 2000-11-09
US6586015B1 (en) 2003-07-01
EP1176972A1 (de) 2002-02-06
EP1176971A1 (de) 2002-02-06
CA2372223A1 (en) 2000-11-09
CN1352563A (zh) 2002-06-05
AU4559300A (en) 2000-11-17
DE50007689D1 (de) 2004-10-14
ATE275411T1 (de) 2004-09-15
EP1176971B1 (de) 2004-09-08
ES2226831T3 (es) 2005-04-01
BR0010604A (pt) 2002-02-05
MXPA01010980A (es) 2003-06-30
CN1364085A (zh) 2002-08-14
BR0010590A (pt) 2003-07-22
WO2000066135A1 (de) 2000-11-09
CA2372220A1 (en) 2000-11-09
JP2002543139A (ja) 2002-12-17
MXPA01010982A (es) 2003-07-21
JP2002543140A (ja) 2002-12-17
DE19919585A1 (de) 2000-12-07
AU4559200A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
PT1176971E (pt) Utilizacao de phyllanthus para o tratamento de processos inflamatorios e fibroticos cronicos
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
DE69711034D1 (de) Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
BR0204869B1 (pt) unidade local de um aparelho de tratamento de ar e aparelho de tratamento de ar.
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
PT1297851E (pt) Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca
BR0202519B1 (pt) métodos para tratamento de material de madeira e para tratamento microbicida de material de madeira.
NO20051681L (no) Lysaldring av hud og aktinskadebehandling
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
BR0213408A (pt) Métodos de prevenção e de tratamento de infecção por flavivìrus em animais
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
NO20012634D0 (no) Nye kreftbehandlinger
DK1326599T3 (da) Anvendelse af aivlosin til behandling eller forebyggelse af Lawsonia-infektioner i grise
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
PT1381620E (pt) Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes
ITTO20010319A0 (it) Procedimento e apparecchiatura per la rivelazione o il riconoscimentodi un oggetto.
BR0117078B1 (pt) mÉtodo para preparaÇço de couro utilizando protease e mÉtodo para tratamento de dejetos derivados do processamento do couro utilizando o mesmo.
AR034375A1 (es) Combinacion de un inhibidor de ptpasa y un agente de sulfonilurea
BR9706050A (pt) Removedor de oxigênio e substância quiímica para o tratamento de água de caldeira
PT1207899E (pt) Tratamento da rinite alergica com certas proteinas de ligacao de aminas vasoactivas
EA200200927A1 (ru) Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
ATE390144T1 (de) Behandlung von fibrosen
NO20051879D0 (no) Anvendelse av proteintyrosinfosfataseinhibitorer til forhindring og/eller behandling av kreft